Pharmacotherapy for social anxiety disorder

Cochrane Database of Systematic Reviews

Volumn 2004, Issue 4, 2004, Pages

  Stein, Dan J ^a   Ipser, Jonathan C ^a   van Balkom, Anton J ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROFAROMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE EFFECTIVENESS; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LIEBOWITZ SOCIAL ANXIETY SCALE; LONG TERM CARE; MENTAL DEFICIENCY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SOCIAL PHOBIA; SYSTEMATIC REVIEW;

EID: 85041809728     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001206.pub2     Document Type: Review

References (118)

1. Allgulander C. Paroxetine in social social anxiety disorder: a randomised placebo-controlled study. Acta Psychiatrica Scandinavica 1999;100(3):193-8.
2. Baldwin D, Bobes J, Stein DJ, Scharwaechter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. British Journal of Psychiatry 1999;175:120-6.
3. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology 2002;16(4):365-8.
4. BlomhoffS, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry 2001;179:23-30.
5. Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. American Journal of Psychiatry 1991;148(5):598-605.
6. Connor KM, Davidson JR, Potts NL, Tupler LA, Miner CM, Malik ML, et al. Discontinuation of clonazepam in the treatment of social phobia. Journal of Clinical Psychopharmacology 1998;18(5):373-8.
7. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, et al. Treatment of social phobia with clonazepan and placebo. Journal of Clinical Psychopharmacology 1993;13(6):423-8.
8. Fahlen T, Nilsson Hl, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatrica Scandinavica 1995;92(5):351-8.
9. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry 1998;55(12):1133-41.
10. James IM, Burgoyne W, Savage IT. Effect on pindolol on stress-related disturbances of musical performance: preliminary communication. Journal of the Royal Society of Medicine 1983;76(3):194-6.
11. Kasper S, Loft H, Smith JR. Escitilopram is efficacious and well tolerated in the treatment of social anxiety disorder. Annual Meeting of the American Psychiatric Association, Philadelphia, PA. 2002.
12. Katschnig K, Stein MB, Buller R. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience 1997;247(2):71-80.
13. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: A double-blind, placebo-controlled crossover study. American Journal of Psychiatry 1995;152(9):1368-71.
14. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. Journal of Clinical Psychopharmacology 2002;22(3):257-62.
15. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Archives of General Psychiatry 1992;49(4):290-300.
16. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry 2002;63(1):66-74.
17. Liebowitz MR, DeMartinis N, Weihs KL, Londborg PD, Smith WT, Chung H, et al. Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2003;64(7):785-92.
18. Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. Journal of Clinical Psychopharmacology 1997;17(4):255-60.
19. Noyes R Jr, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, et al. Moclobemide in social phobia: A controlled dose response trial. Journal of Clinical Psychopharmacology 1997;17(4):247-54.
20. Oosterbaan DB, van Balkom AJLM, Spinhoven P, van Oppen P, van Dyck R. Cognitive therapy versus moclobemide in social phobia: A controlled study. Clinical Pscyhology and Psychotherapy 2001;8:263-273.
21. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. Journal of Clinical Psychopharmacology 1999;19(4):341-8.
22. Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depression & Anxiety 2001;14(4):255-62.
23. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. British Journal of Psychiatry 1998;172:70-7.
24. Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. Journal of Clinical Psychopharmacology 1996;16(3):218-22.
25. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280(8):708-13.
26. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. American Journal of Psychiatry 1999;156(5):756-60.
27. Stein DJ, Cameron A, Amrein R, Montgomery SA. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology 2002;17(4):161-70.
28. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Archives of General Psychiatry 2002;59(12):1111-8.
29. Stein DJ, Westenberg HGM, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12-to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. International Journal of Neuropsychopharmacology 2003;6:317-323.
30. Turner S, Beidel DC, Jacob RG. Social phobia: A comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology 1994;62(2):350-8.
31. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. Sertraline treatment of generalised social phobia: a 20-week, double-blind, placebo-controlled study. American Journal of Psychiatry 2001;158(2):275-81.
32. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. European Neuropsychopharmacology 1992;2(1):21-9.
33. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994;115(1-2):128-34.
34. van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of busiprone in social phobia: a double-blind placebo-controlled study. Journal of Clinical Psychiatry 1997;58(4):164-8.
35. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry 1992;161:353-60.
36. Versiani M, Nardi AE, Figueira I, Mendlowicz M, Marques C. Double-blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria 1997;46(3):167-71.
37. Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, et al. Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology 2000;20(6):636-44.
38. Allsopp LF, Cooper GL, Poole PH. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Current Medical Research and Opinion 1984;9(1):64-70.
39. Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Human Psychopharmacology 2002;2002(8):401-5.
40. Brantigan CO, Brantigan TA, Joseph N. Effects of beta-blockade and beta-stimulation on stage fright. American Journal of Medicine 1982;72(1):88-94.
41. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B. Cognitive therapy versus fluoxetine in generalized social phobia: A randomized placebo-controlled trial. Journal of Consulting and Clinical Psychology 2003;71(6):1058-1067.
42. Falloon IR, Llody GG, Harpin RE. The treatment of social phobia: Real-life rehearsal with nonprofessional therapists. Journal of Nervous and Mental Disease 1981;169(3):180-4.
43. Gates GA, Saegert J, Wilson N, Johnson L, Shepherd A, Hearne EM 3rd. Effect of beta-blockage on singing performance. Annals of Otology, Rhinology and Laryngology 1985;94(6 Pt 1):570-4.
44. Gelernter CS, Uhde TW, Cimbolic P, ArnkoffDB, Vittone BJ, Tancer ME, et al. Cognitive-behavioural and pharmacological treatments of social phobia: A controlled study. Archives of General Psychiatry 1991;48(10):938-45.
45. Hartley LR, Ungapen S, Davie I, Spencer DJ. The effect of beta adrenergic blockade on speaker's performance and memory. British Journal of Psychiatry 1983;142:512-7.
46. James IM, Griffith DN, Pearson RM, Newbury P. Effect of oxprenolol on stage-fright in musicians. Lancet 1977;2(8045):952-4.
47. James I, Savage I. Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo. American Heart Journal 1984;108(4 Pt 2):1150-5.
48. Krishman G. Oxprenolol in the treatment of examination stress. Current Medical Research and Opinion 1976;4:241-3.
49. Krylov V. Pharmacological treatment of social phobia: A controlled study with alprazolam and buspirone. 9th European College of Neuropsychopharmacology, Amsterdam. 1996.
50. Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. Journal of Affective Disorders 2003;76(1-3):279-84.
51. Liden S, Gottfries CG. Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians. Lancet 1974;2(7879):529.
52. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, et al. Pharmacotherpy of social phobia: An interim report of placebo-controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry 1988;49(7):252-7.
53. Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depression and Anxiety 1999;10(3):89-98.
54. Mountjoy CQ, Roth M, Garside RF, Leitch IM. A clinical trial of phenelzine in anxiety depressive and phobic neuroses. British Journal of Psychiatry 1977;131:486-92.
55. Neftel KA, Adler RH, Kappeli L, Rossi M, Dolder M, Kaser HE, et al. Stage fright in musicians: A model illustrating the effect of beta blockers. Psychosomatic Medicine 1982;44(5):461-9.
56. Oosterbaan D, van Balkom A, Spinhoven, van Dyk R. Cognitive behavior therapy versus moclobemide in social phobia. WPA Thematic Conference, Jerusalem, Nov 1997.
57. Otto MW, Pollack MH, Gould RA, Worthington JJ, McArdle ET, Rosenbaum JF, et al. A comparison of the efficacy of clonazepam and cognitive-behavioural group therapy for the treatment of social phobia. Journal of Anxiety Disorders 2000;14(4):345-8.
58. Pecknold JC, McClure DJ, Appeltauer L, Allan T, Wrzesinski L. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and agoraphobicand social pobic patients. British Journal of Psychiatry 1982;140:484-90.
59. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine 2001;34(17):1279-85.
60. Seedat S, Stein M. Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study. American Journal of Psychiatry 2001;158(10):1725-7.
61. Siitonen L, Janne J. Effect of beta-blockade during bowling competition. Annals of Clinical Research 1976;8(6):393-8.
62. Silverstone JT, Salkind MR. Controlled evaluation of intravenous drugs in the specific desensitization of phobias. Canadian Psychiatric Association Journal 1973;18(1):47-53.
63. Solyom L, Heseltine GF, McClure DJ, Solyom C, Ledwidge B, Steinberg G. Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Canadian Psychiatric Association Journal 1973;18(1):25-32.
64. Solyom C, Solyom L, LaPierre Y, Pecknold J, Morton L. Phenelzine and exposure in the treatment of phobias. Biological Psychiatry 1981;16(3):239-47.
65. Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologica 1973;32(3):237-54.
66. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Human Psychopharmacology 2004;19(6):387-396.
67. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology 2005;177(3):280-8.
68. Ongoing study Starting date of trial not provided. Contact author for more information.
69. Ongoing study Starting date of trial not provided. Contact author for more information.
70. Ongoing study Starting date of trial not provided. Contact author for more information.
71. Aarre TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nordic Journal of Psychiatry 2003;57(4):313-315.
72. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Press, 1980.
73. Bailar JC 3rd. The promise and problems of meta-analysis. New England Journal of Medicine 1999;337(8):559-61.
74. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DCet al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry 1998;59 Suppl 17:54-60.
75. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. WFSBP Task Force on Treatment Guidelines for Anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry 2002;3(4):171-99.
76. Berlin JA, Rennie D. Measuring the quality of trials: The quality of quality scales. JAMA 1999;282(11):1083-5.
77. Blanco C, Antia SX, Liebowitz MR. Pharmacotherapy of social anxiety disorder. Biological Psychiatry 2002;51(1):109-20.
78. Blanco C, Schneier FR, Schmidt A, Blanco-Jerez C, Marshall RD, Sanchez-Lacay A, Liebowitz MR. Pharmalogical treatment of social anxiety disorder: A meta-analysis. Depression and Anxiety 2003;18:29-40.
79. Chambless D, Foa E, Groves G, Goldstein A. Flooding with brevital in the treatment of agoraphobia - countereffective?. Behav Res Ther 1979;17:243-251.
80. Davidson JR, Ford SM, Smith RD, Potts NL. Long-term treatment of social phobia with clonazepam. Journal of Clinical Psychiatry 1991;52 Suppl 1:16-20.
81. Davidson JR. Pharmacotherapy of social anxiety disorder. Journal of Clinical Psychiatry 1998;59 Suppl 17:47-51.
82. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2001.
83. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in medicine 2002;21:1575-1600.
84. Deeks J, Higgins J, Altman D. Cochrane Reviewers' Handbook 4.2.1 [updated December 2003]. In: Alderson P, Green S, Higgins J editor(s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2003.
85. Dickersin K, Min YI, Meinert CL. Factors influencing the publication of research results: Follow-up of applications submitted to two substantial review boards. JAMA 1992;267(3):374-8.
86. Easterbrook PJ, Berline JA, Gopalan R, Mathews DR. Publication bias in clinical research. Lancet 1991;337(8746):867-72.
87. Fahlen T. Personality traits in social phobia, II: Changes during drug treatment. Journal of Clinical Psychiatry 1995;56(12):569-73.
88. FedoroffIC, Taylor S. Psychological and pharmacological treatments of social phobia. Journal of Clinical Psychopharmacology 2001;21(3):311-24.
89. Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Archives of General Psychiatry 2002;59(5):425-33.
90. Gorman JM, Gorman LK. Drug treatment of social phobia. Journal of Affective Disorders 1987;13(2):183-92.
91. Gould RA, Buckminister S, Pollack MH, Otto MW, Yap L. Cognitive-behavioral and pharmacological treatments of social phobia. Clinical Psychology - Science & Practice 1997;4(4):291-306.
92. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. National Institute of Health, 1976.
93. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-5.
94. Higgins JT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(6):557-60.
95. Kelsey JE. Venalafaxine in social phobia. Psychopharmacology Bulletin 1995;31(4):767-71.
96. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III.-R psychiatric disorders in the United Sates: results from the National Comorbidity Survey. Archives of General Psychiatry 1994;51(1):8-19.
97. Kuzma JM, Black DW. Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders [Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders]. Curr Psychiatry Rep. 2004;6(4):268-273.
98. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia. Review of a neglected anxiety disorder. Archives of General Psychiatry 1985;42(7):729-36.
99. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry 2002;63(1):66-74.
100. Lincoln TM, Rief W. How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia. Journal of Anxiety Disorders 2004;18(4):515-529.
101. Marks IM, Gelder MG. Different ages of onset in varieties of phobias. American Journal of Psychiatry 1966;123(2):218-21.
102. Matsunaga H, Kiriike N, Matsui T, Iwasaki Y, Stein DJ. Taijin kyofusho: A form of social anxiety disorder that repsonds to serotonin reuptake inhibitors?. International Journal of Neuropsychopharmacology 2001;4(3):231-7.
103. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999;354(9193):1896-900.
104. Mulrow CD, Oxman AD. Cochrane Collaboration Handbook. Oxford: Update Software, 1997.
105. Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented in abstracts. A meta-analysis. JAMA 1994;272(2):158-62.
106. Schneier FR, Blanco C, Campeas R, Lewis-Fernandez R, Lin SH, Marshall R, Schmidt AB, Sanchez-Lacay JA, Simpson HB, Liebowitz MR. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress and Anxiety 2003;17(4):191-196.
107. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. International Clinical Psychopharmacology 1996;11 Suppl 3:89-95.
108. Song F, Altman DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. British Medical Journal 2003;326(7387):472.
109. Stein DJ, Le Roux L, Bouwer C, Van Heerden B. Is olfactory reference syndrome on the obsessive-compulsive spectrum? Two cases and a discussion. Journal of Neuropsychiatry and Clinical Neuroscience 1998;10(1):96-9.
110. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. American Journal of Psychiatry 2001;158(10):1725-7.
111. Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials. Journal of Clinical Psychiatry 2002;63(2):152-5.
112. Stein DJ, Hunter B, Rolfe T, et al. Paroxetine in social anxiety disorder: A remission analysis. Presented at the ECNP Congress, Barcelona, Spain. Oct. 2002.
113. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309(6965):1351-15.
114. Turner SM, Beidel DC, Cooley-Quille MR. Two-year follow-up of social phobias treated with Social Effectiveness Therapy. Behaviour Research and Therapy 1995;33(5):553-5.
115. van Ameringen M, Mancini C, Wilson C. Busiprone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. Journal of Affective Disorders 1996;39(2):115-21.
116. Van Ameringen M, Mancini C. Pharmacotherapy of social anxiety disorder at the turn of the millennium. Psychiatric Clinics of North America 2001;24(4):783-803.
117. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials. International Clinical Psychopharmacology 2000;15 Suppl 2:15-24.
118. Wardle J. Behavior therapy and benzodiazepines: allies or antagonists?. British Journal of Psychiatry 1990;156:163-168.